Epiregulin expression and secretion is increased in castration-resistant prostate cancer.

ABSTRACT:

Introduction

In prostate cancer, long-term treatment directed against androgens often leads to the development of metastatic castration-resistant prostate cancer, which is more aggressive and not curatively treatable. Androgen deprivation results in elevated epiregulin expression in LNCaP cells which is a ligand of EGFR. This study aims to reveal the expression and regulation of epiregulin in different prostate cancer stages enabling a more specific molecular characterization of different prostate carcinoma types.

Methods

Five different prostate carcinoma cell lines were used to characterize the epiregulin expression on the RNA and protein levels. Epiregulin expression and its correlation with different patient conditions were further analyzed using clinical prostate cancer

SUBMITTER: Wiesehofer M 

PROVIDER: S-EPMC10040687 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature